Cambiar Investors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $58.6M | Buy |
1,017,517
+73,271
| +8% | +$4.21M | 2.54% | 4 |
|
|
2026
Q1 | $57.3M | Sell |
944,246
-38,930
| -4% | -$2.27M | 2.65% | 6 |
|
|
2025
Q4 | $53M | Buy |
983,176
+25,841
| +3% | +$1.24M | 2.37% | 11 |
|
|
2025
Q3 | $43.2M | Sell |
957,335
-61,815
| -6% | -$2.89M | 1.96% | 25 |
|
|
2025
Q2 | $47.2M | Buy |
1,019,150
+7,216
| +0.7% | +$354K | 1.98% | 17 |
|
|
2025
Q1 | $61.7M | Sell |
1,011,934
-27,465
| -3% | -$1.6M | 2.62% | 4 |
|
|
2024
Q4 | $58.8M | Buy |
1,039,399
+57,814
| +6% | +$3.23M | 2.33% | 8 |
|
|
2024
Q3 | $50.8M | Buy |
981,585
+195,861
| +25% | +$9.19M | 1.95% | 19 |
|
|
2024
Q2 | $32.6M | Buy |
785,724
+17,582
| +2% | +$787K | 1.28% | 35 |
|
|
2024
Q1 | $41.7M | Sell |
768,142
-38,670
| -5% | -$1.97M | 1.55% | 25 |
|
|
2023
Q4 | $41.4M | Buy |
806,812
+68,299
| +9% | +$3.59M | 1.63% | 24 |
|
|
2023
Q3 | $42.9M | Buy |
738,513
+99,262
| +16% | +$6.08M | 1.82% | 18 |
|
|
2023
Q2 | $40.9M | Buy |
+639,251
| New | +$42.9M | 1.73% | 23 |
|
|
2022
Q2 | – | Sell |
-701,850
| Closed | -$51.3M | – | 148 |
|
|
2022
Q1 | $51.3M | Sell |
701,850
-13,855
| -2% | -$930K | 1.93% | 20 |
|
|
2021
Q4 | $44.6M | Sell |
715,705
-15,215
| -2% | -$893K | 1.53% | 29 |
|
|
2021
Q3 | $43.2M | Sell |
730,920
-627
| -0.1% | -$41.3K | 1.48% | 32 |
|
|
2021
Q2 | $48.9M | Buy |
731,547
+60,019
| +9% | +$3.91M | 1.57% | 29 |
|
|
2021
Q1 | $42.4M | Buy |
671,528
+57,516
| +9% | +$3.58M | 1.48% | 30 |
|
|
2020
Q4 | $38.1M | Buy |
614,012
+213,177
| +53% | +$13.1M | 1.49% | 28 |
|
|
2020
Q3 | $24.2M | Buy |
+400,835
| New | +$24.1M | 1.1% | 45 |
|
|
2018
Q3 | – | Sell |
-560,751
| Closed | -$31M | – | 173 |
|
|
2018
Q2 | $31M | Buy |
560,751
+784
| +0.1% | +$42.3K | 0.52% | 55 |
|
|
2018
Q1 | $35.4M | Sell |
559,967
-124,498
| -18% | -$8.01M | 0.56% | 49 |
|
|
2017
Q4 | $41.9M | Sell |
684,465
-49,425
| -7% | -$3.09M | 0.66% | 41 |
|
|
2017
Q3 | $46.8M | Sell |
733,890
-19,619
| -3% | -$1.15M | 0.73% | 34 |
|
|
2017
Q2 | $42M | Sell |
753,509
-378,937
| -33% | -$20.6M | 0.66% | 45 |
|
|
2017
Q1 | $61.6M | Sell |
1,132,446
-25,059
| -2% | -$1.37M | 1.03% | 29 |
|
|
2016
Q4 | $67.6M | Buy |
1,157,505
+733,300
| +173% | +$40.1M | 1.16% | 20 |
|
|
2016
Q3 | $22.9M | Buy |
+424,205
| New | +$27.2M | 0.33% | 77 |
|
Other funds holding BMY
Cambiar Investors's BMY Position: Q2 2026 in Review
Cambiar Investors increased its Bristol-Myers Squibb (BMY) stake by 7.8% in Q2 2026, buying an estimated $4.21M and bringing the position to 1,017,517 shares worth $58.6M. The position accounts for 2.54% of the portfolio, ranked #4.
Cambiar Investors first reported a position in BMY in Q3 2016 and has held it in 28 quarters since. The position peaked at $67.6M in Q4 2016. 2,521 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Cambiar Investors held 1,017,517 shares of Bristol-Myers Squibb worth $58.6M as of Q2 2026.
- Cambiar Investors bought 73,271 Bristol-Myers Squibb shares in Q2 2026, an estimated $4.21M.
- Bristol-Myers Squibb made up 2.54% of Cambiar Investors's portfolio in Q2 2026, its #4 holding.
- Cambiar Investors first reported a position in Bristol-Myers Squibb in Q3 2016 and has held it in 28 quarters since.
- Cambiar Investors's Bristol-Myers Squibb position peaked at $67.6M in Q4 2016.
- 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Cambiar Investors's 13F filing for Q2 2026, filed 31 Jul 2026.